113 related articles for article (PubMed ID: 16516473)
1. Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors.
Hennequin LF; Ballard P; Boyle FT; Delouvrié B; Ellston RP; Halsall CT; Harris CS; Hudson K; Kendrew J; Pease JE; Ross HS; Smith P; Vincent JL
Bioorg Med Chem Lett; 2006 May; 16(10):2672-6. PubMed ID: 16516473
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors.
Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT
Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of EGFR tyrosine kinase inhibition by C-C multiple bonds-containing anilinoquinazolines.
Ban HS; Tanaka Y; Nabeyama W; Hatori M; Nakamura H
Bioorg Med Chem; 2010 Jan; 18(2):870-9. PubMed ID: 19969465
[TBL] [Abstract][Full Text] [Related]
4. Inhibitors of epidermal growth factor receptor tyrosine kinase: Novel C-5 substituted anilinoquinazolines designed to target the ribose pocket.
Ballard P; Bradbury RH; Harris CS; Hennequin LF; Hickinson M; Johnson PD; Kettle JG; Klinowska T; Leach AG; Morgentin R; Pass M; Ogilvie DJ; Olivier A; Warin N; Williams EJ
Bioorg Med Chem Lett; 2006 Mar; 16(6):1633-7. PubMed ID: 16380259
[TBL] [Abstract][Full Text] [Related]
5. A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Barlaam B; Ballard P; Bradbury RH; Ducray R; Germain H; Hickinson DM; Hudson K; Kettle JG; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Pearson SE; Scott JS; Suleman A; Trigwell CB; Vautier M; Whittaker RD; Wood R
Bioorg Med Chem Lett; 2008 Jan; 18(2):674-8. PubMed ID: 18061446
[TBL] [Abstract][Full Text] [Related]
6. 5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase.
Ballard P; Bradbury RH; Hennequin LF; Hickinson DM; Johnson PD; Kettle JG; Klinowska T; Morgentin R; Ogilvie DJ; Olivier A
Bioorg Med Chem Lett; 2005 Oct; 15(19):4226-9. PubMed ID: 16055332
[TBL] [Abstract][Full Text] [Related]
7. Tyrosine kinase inhibitors. 11. Soluble analogues of pyrrolo- and pyrazoloquinazolines as epidermal growth factor receptor inhibitors: synthesis, biological evaluation, and modeling of the mode of binding.
Palmer BD; Trumpp-Kallmeyer S; Fry DW; Nelson JM; Showalter HD; Denny WA
J Med Chem; 1997 May; 40(10):1519-29. PubMed ID: 9154973
[TBL] [Abstract][Full Text] [Related]
8. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.
Hennequin LF; Stokes ES; Thomas AP; Johnstone C; Plé PA; Ogilvie DJ; Dukes M; Wedge SR; Kendrew J; Curwen JO
J Med Chem; 2002 Mar; 45(6):1300-12. PubMed ID: 11881999
[TBL] [Abstract][Full Text] [Related]
9. Allene as an alternative functional group for drug design: effect of C--C multiple bonds conjugated with quinazolines on the inhibition of EGFR tyrosine kinase.
Ban HS; Onagi S; Uno M; Nabeyama W; Nakamura H
ChemMedChem; 2008 Jul; 3(7):1094-103. PubMed ID: 18465761
[TBL] [Abstract][Full Text] [Related]
10. Neutral 5-substituted 4-indazolylaminoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Barlaam B; Acton DG; Ballard P; Bradbury RH; Cross D; Ducray R; Germain H; Hudson K; Klinowska T; Magnien F; Ogilvie DJ; Olivier A; Ross HS; Smith R; Trigwell CB; Vautier M; Wright L
Bioorg Med Chem Lett; 2008 Mar; 18(6):1799-803. PubMed ID: 18313293
[TBL] [Abstract][Full Text] [Related]
11. Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase.
Ballard P; Barlaam BC; Bradbury RH; Dishington A; Hennequin LF; Hickinson DM; Hollingsworth IM; Kettle JG; Klinowska T; Ogilvie DJ; Pearson SE; Scott JS; Suleman A; Whittaker R; Williams EJ; Wood R; Wright L
Bioorg Med Chem Lett; 2007 Nov; 17(22):6326-9. PubMed ID: 17869514
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and biological evaluation of novel 4-anilinoquinazolines with C-6 urea-linked side chains as inhibitors of the epidermal growth factor receptor.
Zhang X; Peng T; Ji X; Li J; Tong L; Li Z; Yang W; Xu Y; Li M; Ding J; Jiang H; Xie H; Liu H
Bioorg Med Chem; 2013 Dec; 21(24):7988-98. PubMed ID: 24183742
[TBL] [Abstract][Full Text] [Related]
13. High-affinity epidermal growth factor receptor (EGFR) irreversible inhibitors with diminished chemical reactivities as positron emission tomography (PET)-imaging agent candidates of EGFR overexpressing tumors.
Mishani E; Abourbeh G; Jacobson O; Dissoki S; Ben Daniel R; Rozen Y; Shaul M; Levitzki A
J Med Chem; 2005 Aug; 48(16):5337-48. PubMed ID: 16078851
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors.
Kitano Y; Suzuki T; Kawahara E; Yamazaki T
Bioorg Med Chem Lett; 2007 Nov; 17(21):5863-7. PubMed ID: 17869510
[TBL] [Abstract][Full Text] [Related]
15. 7-Substituted-[1,4]dioxano[2,3-g]quinazolines as inhibitors of epidermal growth factor receptor kinase.
Lee JY; Park YK; Seo SH; Yang BS; Park H; Lee YS
Arch Pharm (Weinheim); 2002 Dec; 335(10):487-94. PubMed ID: 12506397
[TBL] [Abstract][Full Text] [Related]
16. Determination of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase, in human Caco-2 monolayers by high performance liquid chromatography with ultraviolet detection: application to a trans-epithelial transport study.
Sun HY; Guan S; Bi HC; Su QB; Huang WL; Chowbay B; Huang M; Chen X; Li CG; Zhou SF
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jul; 854(1-2):320-7. PubMed ID: 17467348
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and anti-proliferative activity of substituted-anilinoquinazolines and its relation to EGFR inhibition.
El Ella DA; Saleh KA; Hassan M; Hamdy N; El-Araby ME; Abouzid KA
Arzneimittelforschung; 2012 Aug; 62(8):360-6. PubMed ID: 22723174
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of bis(methoxy methyl)-7,8-dihydro-[1,4]dioxino[2,3-g]quinazolines as EGFR tyrosine kinase inhibitors.
Lee YS; Seo SH; Yang BS; Lee JY
Arch Pharm (Weinheim); 2005 Oct; 338(10):502-5. PubMed ID: 16211656
[TBL] [Abstract][Full Text] [Related]
19. Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors.
Lüth A; Löwe W
Eur J Med Chem; 2008 Jul; 43(7):1478-88. PubMed ID: 17981366
[TBL] [Abstract][Full Text] [Related]
20. Novel EGFR inhibitors prepared by combination of dithiocarbamic acid esters and 4-anilinoquinazolines.
Li RD; Zhang X; Li QY; Ge ZM; Li RT
Bioorg Med Chem Lett; 2011 Jun; 21(12):3637-40. PubMed ID: 21570843
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
